Carnival Corp vs ResMed Inc. — how do they compare? Carnival Corp trades at $27.77 (market cap $37.98B), while ResMed Inc. trades at $226.29 (market cap $32.61B). The key difference: Carnival Corp is the larger of the two by market cap, and Carnival Corp pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| CCL | RMD | |
|---|---|---|
Market Cap | $37.98B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $293.73 |
52-Week Low | $23.89 | $182.82 |
Enterprise Value | $61.91B | $31.97B |
Dividend Yield | 1.62% | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.82, showing modest daily gains of 0.25%. The stock maintains strong fundamental momentum with consecutive earnings beats in recent quarters (Q4 2025 and Q1 2026) and improving profitability trends. Technical indicators show a bearish bias in moving averages while oscillators remain neutral. The company demonstrates robust operational recovery with revenue growth from $12.2B in 2022 to $26.6B in 2025, and positive net cash flow of $727M in 2025 after years of negative cash flow.
CCL presents a compelling recovery story with analyst consensus pointing to 26% upside to the $35.18 price target. Investment opportunities include sustained travel demand, fleet expansion, and debt reduction progress. Key risks involve fuel price volatility, competitive pressures, and execution of growth initiatives amid economic uncertainty. The stock's attractive valuation (P/E 12.49x) and 59.6% analyst buy rating support a positive medium-term outlook.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →